Trials / Completed
CompletedNCT02093169
D2 Dopamine Receptor Occupancy After Oral Dosing of Lu AF35700 in Healthy Men Using [11C]-PHNO as Tracer Compound
Interventional, Open-label, Positron Emission Tomography (PET) Study Investigating D2 Dopamine Receptor Occupancy After Oral Dosing of Lu AF35700 in Healthy Men Using [11C]-PHNO as Tracer Compound
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- H. Lundbeck A/S · Industry
- Sex
- Male
- Age
- 25 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
To investigate the relationship between the combined Lu AF35700 and Lu AF36152 plasma concentration and D2 dopamine receptor occupancy up to 172 hours after oral dosing of Lu AF35700
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Part A: Lu AF35700 | One 30 mg single dose for one day; orally |
| DRUG | Part B: Lu AF35700 | Daily dosing: 10 mg for 3 days, 20 mg for 3 days, 45 mg on Day 7; orally |
Timeline
- Start date
- 2014-02-01
- Primary completion
- 2014-06-01
- First posted
- 2014-03-20
- Last updated
- 2014-09-23
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT02093169. Inclusion in this directory is not an endorsement.